InBody Co.,Ltd (041830.KQ)
KRW 23500.0
(1.08%)
KRW 23500.0
(1.08%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 44.46 Billion KRW | -5.91% |
| 2022 | 40.7 Billion KRW | 13.53% |
| 2021 | 35.85 Billion KRW | 89.47% |
| 2020 | 18.92 Billion KRW | -31.37% |
| 2019 | 27.57 Billion KRW | 16.46% |
| 2018 | 23.67 Billion KRW | -4.38% |
| 2017 | 24.76 Billion KRW | 12.34% |
| 2016 | 22.04 Billion KRW | 10.16% |
| 2015 | 20 Billion KRW | 98.19% |
| 2014 | 10.09 Billion KRW | 55.8% |
| 2013 | 6.47 Billion KRW | 29.54% |
| 2012 | 5 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 9.61 Billion KRW | 28.9% |
| 2024 Q2 | 8.9 Billion KRW | -2.07% |
| 2023 Q2 | 8.38 Billion KRW | -17.65% |
| 2023 Q1 | 10.17 Billion KRW | -13.22% |
| 2023 FY | 38.29 Billion KRW | -5.91% |
| 2023 Q3 | 12.28 Billion KRW | 46.55% |
| 2023 Q4 | 7.45 Billion KRW | -39.28% |
| 2022 Q3 | 7.54 Billion KRW | -24.17% |
| 2022 Q1 | 11.51 Billion KRW | 28.56% |
| 2022 FY | 40.7 Billion KRW | 13.53% |
| 2022 Q4 | 11.72 Billion KRW | 55.53% |
| 2022 Q2 | 9.94 Billion KRW | -13.66% |
| 2021 Q4 | 8.95 Billion KRW | 13.62% |
| 2021 Q1 | 10.24 Billion KRW | 65.78% |
| 2021 FY | 35.85 Billion KRW | 89.47% |
| 2021 Q2 | 8.76 Billion KRW | -14.51% |
| 2021 Q3 | 7.88 Billion KRW | -10.01% |
| 2020 Q1 | 5.58 Billion KRW | 12.42% |
| 2020 Q3 | 6.83 Billion KRW | 1590.9% |
| 2020 Q4 | 6.18 Billion KRW | -9.59% |
| 2020 FY | 18.92 Billion KRW | -31.37% |
| 2020 Q2 | 404.34 Million KRW | -92.77% |
| 2019 Q4 | 4.97 Billion KRW | -35.76% |
| 2019 Q3 | 7.73 Billion KRW | -8.26% |
| 2019 FY | 27.57 Billion KRW | 16.46% |
| 2019 Q1 | 6.47 Billion KRW | 22.88% |
| 2019 Q2 | 8.43 Billion KRW | 30.23% |
| 2018 Q1 | 4.55 Billion KRW | -40.1% |
| 2018 Q3 | 7.26 Billion KRW | 10.41% |
| 2018 Q2 | 6.58 Billion KRW | 44.38% |
| 2018 FY | 23.67 Billion KRW | -4.38% |
| 2018 Q4 | 5.27 Billion KRW | -27.44% |
| 2017 FY | 24.76 Billion KRW | 12.34% |
| 2017 Q4 | 7.6 Billion KRW | 8.8% |
| 2017 Q2 | 5.81 Billion KRW | 29.91% |
| 2017 Q1 | 4.47 Billion KRW | 3.75% |
| 2017 Q3 | 6.99 Billion KRW | 20.22% |
| 2016 Q4 | 4.31 Billion KRW | -6.5% |
| 2016 FY | 22.04 Billion KRW | 10.16% |
| 2016 Q3 | 4.61 Billion KRW | -11.85% |
| 2016 Q2 | 5.23 Billion KRW | -33.47% |
| 2016 Q1 | 7.87 Billion KRW | 33.52% |
| 2015 Q4 | 5.89 Billion KRW | 3.46% |
| 2015 FY | 20 Billion KRW | 98.19% |
| 2015 Q1 | 4.27 Billion KRW | 316.03% |
| 2015 Q2 | 4.13 Billion KRW | -3.2% |
| 2015 Q3 | 5.69 Billion KRW | 37.67% |
| 2014 Q1 | 3.49 Billion KRW | 246.85% |
| 2014 Q2 | 3.15 Billion KRW | -9.92% |
| 2014 Q3 | 2.41 Billion KRW | -23.3% |
| 2014 Q4 | 1.02 Billion KRW | -57.48% |
| 2014 FY | 10.09 Billion KRW | 55.8% |
| 2013 Q1 | 2.47 Billion KRW | 420.8% |
| 2013 Q4 | 1 Billion KRW | -49.24% |
| 2013 FY | 6.47 Billion KRW | 29.54% |
| 2013 Q2 | 1 Billion KRW | -59.38% |
| 2013 Q3 | 1.98 Billion KRW | 97.48% |
| 2012 Q3 | 1.41 Billion KRW | 0.0% |
| 2012 Q4 | 475.67 Million KRW | -66.42% |
| 2012 FY | 5 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 142.82 Billion KRW | 68.866% |
| Curexo Inc. | 1.13 Billion KRW | -3816.359% |
| Seegene, Inc. | -30 Billion KRW | 248.184% |
| i-SENS, Inc. | 10.92 Billion KRW | -306.864% |
| Ray Co., Ltd. | 6.11 Billion KRW | -626.794% |
| Gencurix Inc. | -12.37 Billion KRW | 459.309% |
| Sugentech Inc. | -22.74 Billion KRW | 295.533% |
| L&C Bio Co., Ltd | 6.66 Billion KRW | -567.002% |